Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost
1998

Benefits of G-CSF After High-Dose Chemotherapy for Lymphoma

Sample size: 23 publication Evidence: moderate

Author Information

Author(s): SM Lee, JA Radford, L Dobson, T Huq, WDJ Ryder, R Pettengell, GR Morgenstern, JH Scarffe, D Crowther

Primary Institution: Christie Hospital NHS Trust

Hypothesis

Does the use of G-CSF after high-dose chemotherapy improve recovery and reduce costs in patients with high-grade non-Hodgkin's lymphoma?

Conclusion

The use of G-CSF after high-dose chemotherapy leads to faster recovery and shorter hospital stays without increasing healthcare costs.

Supporting Evidence

  • Patients receiving G-CSF had a mean recovery time of 9.7 days compared to 13.2 days for those without G-CSF.
  • The median duration of hospital stay was shorter for the G-CSF group at 12 days versus 15 days for the control group.
  • Despite the cost of G-CSF, the overall healthcare expenditure was lower in the G-CSF group.

Takeaway

Giving G-CSF helps patients recover faster after chemotherapy and they spend less time in the hospital, which is good for both them and the hospital's budget.

Methodology

A prospective randomized trial comparing PBPC alone versus PBPC with G-CSF in patients with high-grade non-Hodgkin's lymphoma.

Limitations

The study had a small sample size and was limited to patients under 60 years old.

Participant Demographics

Patients were aged less than 60 years with poor-prognosis high-grade non-Hodgkin's lymphoma.

Statistical Information

P-Value

p<0.0001

Confidence Interval

95% CI of 2.2-4.8 days for granulocyte recovery time

Statistical Significance

p<0.0001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication